The UK and US have finalized a major trade agreement that will ensure no duties on British medicine exports entering the American market.
The Terms of the Accord
Under the terms of the agreement, the UK has agreed to boost funding on medicines through the National Health Service (NHS). This move secures that import taxes on these vital products will stay at zero for a period of three years.
This deal comes after recent threats to hike tariffs on patented drug products, with potential rates discussed reaching 100%.
"This deal between the Britain strengthens the global environment for cutting-edge drugs and establishes much-needed equity to transatlantic medicine commerce," an announcement noted.
Trade Impact
Medicines represent one of the Britain's largest exports to the America, which is by far the primary market for leading British pharmaceutical firms.
Statistics show that in the one-year period to the end of the third quarter, the UK exported pharmaceutical products valued at over eleven billion pounds to the US. This figure accounted for 17.4% of British export trade in that timeframe.
"This agreement safeguards jobs, stimulates investment and paves the way for the UK to establish itself as a global hub for biotech and pharma," the Business and Trade Secretary remarked.
Specific UK Commitments
The agreement entails several notable changes from the United Kingdom:
- Revised Affordability Limit: The UK will raise the price threshold at which it considers new therapies to be unaffordable by a quarter.
- Increased NHS Spending: There is a target to double overall health service expenditure on treatments from 0.3 percent of GDP to 0.6 percent over the following ten-year period.
- Rebate Cap: The sum manufacturers must return to the NHS to stay within budget will be capped at 15%. Previously, repayments were more than 20%.
Industry Background
The pact comes amid a ongoing dispute between the pharmaceutical industry and the UK government over medicine costs and approval rates.
This friction were intensified by claims that US patients were charged a premium for the identical medicines than consumers in the UK and Europe.
In recent months, several major drug company projects in the UK have been paused or scrapped, while major funding commitments have been pledged toward American operations.
A senior figure publicly accepted that the NHS had to spend more on drugs, noting that its budget allocation on drugs had decreased as a proportion of its overall budget over the past decade.
